New Horizon Health (HKG:6606) Full Year 2022 Results
Key Financial Results
- Revenue: CN¥765.0m (up 260% from FY 2021).
- Net loss: CN¥79.2m (loss narrowed by 97% from FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
New Horizon Health Revenues Beat Expectations
Revenue exceeded analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are down 12% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for New Horizon Health that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if New Horizon Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.